Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan

Intervirology

Volumn 46, Issue 3, 2003, Pages 182-189

  Suzuki, Fumitaka ^a   Tsubota, Akihito ^a   Arase, Yasuji ^a   Suzuki, Yoshiyuki ^a   Akuta, Norio ^a   Hosaka, Tetsuya ^a   Someya, Takashi ^a   Kobayashi, Masahiro ^a   Saitoh, Satoshi ^a   Ikeda, Kenji ^a   Kobayashi, Mariko ^a   Matsuda, Marie ^a   Satoh, Junko ^a   Takagi, Kimiko ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Hepatitis B e antigen; Hepatitis B virus; Lamivudine; Multivariate analysis; Resistance, lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; DNA DETERMINATION; DNA PROBE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; JAPAN; KAPLAN MEIER METHOD; LONG TERM CARE; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; VIRUS MUTATION; VIRUS RESISTANCE;

ADULT; AGED; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; JAPAN; LAMIVUDINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 0042743964     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071460     Document Type: Article

References (34)

1. Beasley RP, Hwang LW, Lin CC, Chien CS: Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 1981;ii:1129-1233.
2. Lok ASF, Chung HT, Liu VWS, Ma OCK: Long-term follow-up of chronic hepatitis B treated with interferon alpha. Gastroenterology 1993;105:1833-1888.
3. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M: A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
4. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF, the Asia Hepatitis Lamivudine Study Group: A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-68.
5. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HWL, Goodman Z, Crowther L, Condrey LD, Woessner M, Rubin M, Brown NA, the US Lamivudine Investigator Group: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
6. Suzuki Y, Kumada H, Ikeda K, Chayama K, Arase Y, Saitoh S, Tsubota A, Kobayashi M, Koike M, Ogawa N, Tanikawa K: Histological changes in liver biopsies after 1 year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999;30:743-748.
7. Song B-C, Suh DJ, Lee HC, Chung Y-H, Lee YS: Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-807.
8. Honkoop P, Man RA, Niesters HGM, Zondervan PE, Schalm SW: Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-639.
9. Hoofnagle JH, Di Bisceglie AM: Treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-356.
10. Leung NWY, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN, the Asia Hepatitis Lamivudine Study Group: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001;33:1527-1532.
11. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW: Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997;26:1393-1395.
12. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H: Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and retakeover by wild type after cessation of therapy. Hepatology 1998;27:1711-1716.
13. Liaw YF, Leung NW, Chag TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL for the Asia Hepatitis Lamivudine Study Group: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-180.
14. Kao JH, Chen PJ, Lai MY, Chen DS: Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554-559.
15. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS: Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000;33:998-1002.
16. Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, Suzuki F, Akuta N, Someya T, Matsuda M, Satoh J, Kumada H: Clinical chracteristics of patients infected with hepatitis B virus genotypes A, B and C. J Gastroenterol 2002;37:35-39.
17. Zöllner B, Petersen J, Schräfer M, Laufs R, Schoder V, Feucht HH: 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 2001;357:934-935.
18. Zöllner B, Petersen J, Schäfer P, Schröter M, Laufs R, Sterneck M, Feucht HH: Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment. Clin Infect Dis 2002;34:1273-1277.
19. Kao JH, Liu CJ, Chen DS: Hepatitis B virus genotype and lamivudine resistance. J Hepatol 2002;36:303-304.
20. Nafa S, Ahmed S, Tavan D, Pichouc C, Berby F, Stuyver L, Johnson M, Merle P, Abidi H, Trépo C, Zoulim F: Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000;32:1078-1088.
21. Puchhammer-Stöckl E, Mandl CW, Kletzmayr J, Holzmann H, Hofmann A, Aberle SW, Heinz FX, Watschinger B, Hofmann H: Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy. J Infect Dis 2000;181:2063-2066.
22. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL: Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-791.
23. Cox DR: Regression models and life tables. J R Stat Soc 1972;34:248-275.
24. Tsubota A, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Chayama K, Murashima N, Ikeda K, Kobayashi M, Kumada H: Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: A preliminary study. Am J Gastroenterol 2001;96:557-562.
25. Usuda S, Okamoto H, Imawari H, Baba K, Tsuda F, Miyakawa Y, Mayumi M: Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in preS2-region product. J Virol Methods 1999;80:97-112.
26. Chien RN, Liaw YF, Atkins M, the Asian Hepatitis Lamivudine Trial Group: Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999;30:770-774.
27. Lau DTY, Khokhar F, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH: Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-834.
28. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin BD, Hawley S, Barber J, Condreay L, Gray DF, Lamivudine Precore Mutant Study Group: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999;29:889-896.
29. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G: Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32:300-306.
30. Rizzetto M: Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. J Med Virol 2002;66:435-451.
31. Lindh M, Hannoun C, Dhillon AP, Norkans G, Horal P: Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999;179:775-782.
32. Chu CJ, Hussain M, Lok ASF: Hepatitis B virus genotype is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002;122: 1756-1762.
33. Orito E, Ichida T, Sakugawa H, Sata M, Horiike N, Hino K, Okita K, Okanoue T, Iino S, Tanaka E, Suzuki K, Watanabe H, Hige S, Mizokami M: Geographic distribution of hepatitis B virus (HBV) genotypes in patients with chronic HBV infection in Japan. Hepatology 2001;34:590-594.
34. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, Heathcote EJ, Brown NA, Atkins M, Woessner M, Gardner SD: Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-194.